PET/CT Predicts Response to Drug Combo in HER2-Positive Breast Cancer

July 13, 2015

The combination of lapatinib plus trastuzumab for patients with metastatic HER2-positive breast cancer resulted in high response rates when used early. Additionally, undergoing [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) 1 week into therapy could predict response to this treatment.

These results from the phase II Translational Breast Cancer Research Consortium (TBCRC) 003 trial were published in the Journal of Clinical Oncology. 

Read the full story.